16 Participants Needed

Triple Drug Therapy for Thyroid Cancer

Recruiting at 9 trial locations
ES
DP
Overseen ByDavic Pfister, MD
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: Memorial Sloan Kettering Cancer Center
Must be taking: Dabrafenib, Trametinib
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

Do I need to stop my current medications to join the trial?

The trial protocol does not specify if you need to stop taking your current medications. However, if you are HIV-positive and on antiretroviral therapy, you are not eligible to participate.

What data supports the effectiveness of the drug combination used in the Triple Drug Therapy for Thyroid Cancer?

The combination of dabrafenib and trametinib has been approved for treating BRAF V600E-mutant anaplastic thyroid cancer, showing effectiveness in clinical studies. This suggests that the combination of these drugs can be beneficial for certain types of thyroid cancer.12345

Is the triple drug therapy for thyroid cancer safe?

The combination of dabrafenib and trametinib has been generally well tolerated in patients with thyroid cancer, with common side effects including fatigue, fever, and nausea. However, there have been rare cases of serious neurological side effects like Guillain-Barre syndrome, which is important for patients and doctors to be aware of.46789

What makes the triple drug therapy for thyroid cancer unique?

The triple drug therapy for thyroid cancer is unique because it combines Cemiplimab, Dabrafenib, and Trametinib, which target different pathways involved in cancer growth. Cemiplimab is an immunotherapy that helps the immune system attack cancer cells, while Dabrafenib and Trametinib target specific proteins involved in cell growth, making this combination potentially more effective than using each drug alone.1011121314

What is the purpose of this trial?

This study is being done to see if adding the study drug, cemiplimab, to the standard therapy with dabrafenib and trametinib is an effective treatment against anaplastic thyroid cancer.

Research Team

Eric J. Sherman, MD - MSK Head and Neck ...

Eric Sherman, MD

Principal Investigator

Memorial Sloan Kettering Cancer Center

Eligibility Criteria

This trial is for adults with anaplastic thyroid cancer that has a specific BRAF-V600E mutation. It's open to those who haven't been cured by surgery, can undergo biopsies, and have measurable disease. Participants need normal heart function and organ health, must not be pregnant, agree to use contraception, and be able to take oral meds.

Inclusion Criteria

My organ and bone marrow functions are normal.
I can swallow and keep down pills.
Negative pregnancy test within 14 days of registration for women of childbearing potential
See 8 more

Exclusion Criteria

I have been treated with dabrafenib and trametinib.
I do not have any severe illnesses that would stop me from following the study's requirements.
I have interstitial lung disease or pneumonitis.
See 8 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive cemiplimab in combination with dabrafenib and trametinib

24 months

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

  • Cemiplimab
  • Dabrafenib
  • Trametinib
Trial Overview The study tests if adding cemiplimab (a new drug) to standard treatment with dabrafenib and trametinib improves outcomes in anaplastic thyroid cancer. Patients will receive this combination therapy and their response will be monitored.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: BRAF-mutant ATCExperimental Treatment2 Interventions
Participants will have a diagnosis of BRAF-V600E mutant Anaplastic Thyroid Cancer

Cemiplimab is already approved in European Union, United States, Canada, Brazil for the following indications:

🇪🇺
Approved in European Union as Libtayo for:
  • Cutaneous squamous cell carcinoma (CSCC)
  • Non-small cell lung cancer (NSCLC)
🇺🇸
Approved in United States as Libtayo for:
  • Cutaneous squamous cell carcinoma (CSCC)
  • Basal cell carcinoma (BCC)
  • Non-small cell lung cancer (NSCLC)
🇨🇦
Approved in Canada as Libtayo for:
  • Cutaneous squamous cell carcinoma (CSCC)
  • Non-small cell lung cancer (NSCLC)
🇧🇷
Approved in Brazil as Libtayo for:
  • Cutaneous squamous cell carcinoma (CSCC)

Find a Clinic Near You

Who Is Running the Clinical Trial?

Memorial Sloan Kettering Cancer Center

Lead Sponsor

Trials
1,998
Recruited
602,000+

Findings from Research

In a study of 36 patients with BRAF V600E-mutant anaplastic thyroid cancer, the combination of dabrafenib and trametinib showed a significant overall response rate of 56%, with three patients achieving complete responses.
The treatment demonstrated manageable safety, with no new adverse effects identified, and improved median progression-free survival of 6.7 months and overall survival of 14.5 months, indicating it is a promising option for this aggressive cancer.
Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study.Subbiah, V., Kreitman, RJ., Wainberg, ZA., et al.[2022]
In a phase 2 trial involving 53 patients with BRAF-mutated radioactive iodine refractory differentiated thyroid cancer, both dabrafenib monotherapy and the combination of dabrafenib + trametinib showed similar objective response rates, with 42% and 48% respectively, indicating no significant advantage of the combination therapy.
The most common side effects included skin disorders and fever, but there were no treatment-related deaths, suggesting that both treatment options are relatively safe for patients.
Dabrafenib Versus Dabrafenib + Trametinib in BRAF-Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2, Open-Label Multicenter Trial.Busaidy, NL., Konda, B., Wei, L., et al.[2023]
In a phase II trial involving 16 patients with BRAF V600E-mutated anaplastic thyroid cancer, the combination of dabrafenib and trametinib showed a high overall response rate of 69%, indicating significant efficacy in a cancer type with previously limited treatment options.
The treatment was well tolerated, with common side effects including fatigue, fever, and nausea, and no new safety concerns were identified, marking a promising advancement for this aggressive cancer.
Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.Subbiah, V., Kreitman, RJ., Wainberg, ZA., et al.[2022]

References

Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond. [2023]
The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells. [2022]
Thyroid Cancers: From Surgery to Current and Future Systemic Therapies through Their Molecular Identities. [2023]
Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. [2022]
5.United Arab Emiratespubmed.ncbi.nlm.nih.gov
Clinical and Translational Challenges in Thyroid Cancer. [2020]
Dabrafenib Versus Dabrafenib + Trametinib in BRAF-Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2, Open-Label Multicenter Trial. [2023]
Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer. [2022]
Advances in targeted therapy for anaplastic thyroid carcinoma. [2022]
Guillain-Barre Syndrome Secondary to the Use of Dabrafenib and Trametinib for the Treatment of Advanced Thyroid Carcinoma. [2023]
10.United Statespubmed.ncbi.nlm.nih.gov
Birinapant Enhances Gemcitabine's Antitumor Efficacy in Triple-Negative Breast Cancer by Inducing Intrinsic Pathway-Dependent Apoptosis. [2022]
Current landscape of personalized clinical treatments for triple-negative breast cancer. [2022]
PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening. [2021]
HDAC6 inhibition enhances the anti-tumor effect of eribulin through tubulin acetylation in triple-negative breast cancer cells. [2021]
14.United Statespubmed.ncbi.nlm.nih.gov
Incidence, risk factors, and management of alpelisib-associated hyperglycemia in metastatic breast cancer. [2023]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security